Format

Send to

Choose Destination
Autoimmun Rev. 2016 Jul;15(7):695-703. doi: 10.1016/j.autrev.2016.03.004. Epub 2016 Mar 9.

Primary Sjӧgren's syndrome: Clinical phenotypes, outcome and the development of biomarkers.

Author information

1
Department of Pathophysiology, School of Medicine, University of Athens, Mikras Asias Str 75, Athens 115 27, Greece. Electronic address: agoules@med.uoa.gr.
2
Department of Pathophysiology, School of Medicine, University of Athens, Mikras Asias Str 75, Athens 115 27, Greece. Electronic address: agtzi@med.uoa.gr.

Abstract

Primary Sjӧgren's syndrome (pSS) is a complex autoimmune disease with distinct clinical phenotypes and variable outcomes. The systemic form of the disease is characterized by immune complex mediated manifestations and is complicated by lymphoma as a result of a polyclonal B cell hyperactivity that is evolving into B cell malignancy. In the past decades, well-established clinical and serological markers have been described in the literature to identify high-risk patients and to predict lymphoma development. However, specific biologic treatments have proven ineffective to control the disease. Significant research effort has been made to reveal the major underlying biological events in this subgroup and identify biomarkers for early diagnosis, prognosis and response to treatment. In this review, we summarize the current data for the proposed histological, molecular and genetic biomarkers.

KEYWORDS:

Biomarkers; Lymphoma; Predictors; Primary Sjӧgren's syndrome; Systemic manifestations

PMID:
26970487
DOI:
10.1016/j.autrev.2016.03.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center